US6824976B1
(en)
|
1993-04-02 |
2004-11-30 |
Rigel Pharmaceuticals, Inc. |
Method for selective inactivation of viral replication
|
US6639061B1
(en)
|
1999-07-07 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate oligomers and related compounds
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US6576752B1
(en)
*
|
1997-02-14 |
2003-06-10 |
Isis Pharmaceuticals, Inc. |
Aminooxy functionalized oligomers
|
US6326478B1
(en)
|
1998-07-08 |
2001-12-04 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
US6277967B1
(en)
|
1998-07-14 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
|
DE19956568A1
(de)
*
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US6465628B1
(en)
*
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
US20040082774A1
(en)
*
|
1999-03-16 |
2004-04-29 |
Guzaev Andrei P. |
Novel phosphate and thiophosphate protecting groups
|
US6121437A
(en)
*
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
US6610842B1
(en)
*
|
1999-05-06 |
2003-08-26 |
Isis Pharmaceuticals, Inc. |
Processes for the synthesis of oligomers using phosphoramidite compositions
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6593466B1
(en)
*
|
1999-07-07 |
2003-07-15 |
Isis Pharmaceuticals, Inc. |
Guanidinium functionalized nucleotides and precursors thereof
|
US6617442B1
(en)
*
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
DE10100586C1
(de)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US7423142B2
(en)
*
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7767802B2
(en)
*
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
US9150605B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
AU2003291755A1
(en)
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
ES2905724T3
(es)
|
2003-06-13 |
2022-04-11 |
Alnylam Europe Ag |
Acido ribonucleico bicatenario con elevada eficacia en un organismo
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
CA2561741C
(en)
|
2004-04-05 |
2016-09-27 |
Alnylam Pharmaceuticals, Inc. |
Processes and reagents for oligonucleotide synthesis and purification
|
JP4584987B2
(ja)
|
2004-04-30 |
2010-11-24 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
C5修飾ピリミジンを含むオリゴヌクレオチド
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7427675B2
(en)
*
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US7923206B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
CA2620856C
(en)
|
2005-08-29 |
2017-11-28 |
Isis Pharmaceuticals, Inc. |
Methods for use in modulating mir-122a
|
DK1931780T3
(en)
|
2005-08-29 |
2016-01-25 |
Regulus Therapeutics Inc |
Antisense-forbindelser med forøget anti-microrna-aktivitet
|
JP5111385B2
(ja)
*
|
2005-10-28 |
2013-01-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ハンチンチン遺伝子の発現を抑制するための組成物および方法
|
EP1942948A4
(de)
*
|
2005-11-04 |
2010-03-03 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur hemmung der expression des nav1.8-genes
|
EP1945270B1
(de)
|
2005-11-09 |
2011-05-25 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen
|
EP2388327A1
(de)
|
2006-01-27 |
2011-11-23 |
Isis Pharmaceuticals, Inc. |
Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von microRNAs
|
CA2663601C
(en)
|
2006-09-22 |
2014-11-25 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by rna interference
|
US10131904B2
(en)
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
US8846639B2
(en)
*
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
WO2010006973A2
(en)
*
|
2008-07-15 |
2010-01-21 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of tgf-beta receptor genes
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
US10138485B2
(en)
*
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
EP2358398A2
(de)
|
2008-10-24 |
2011-08-24 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen und verfahren
|
CA2743249A1
(en)
*
|
2008-11-17 |
2010-05-20 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of factor vii genes
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
CN102307996A
(zh)
*
|
2009-02-03 |
2012-01-04 |
弗·哈夫曼-拉罗切有限公司 |
用于抑制ptp1b基因表达的组合物和方法
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
US20120021515A1
(en)
|
2009-02-06 |
2012-01-26 |
Swayze Eric E |
Oligomeric compounds and methods
|
CN102427852A
(zh)
*
|
2009-05-15 |
2012-04-25 |
霍夫曼-拉罗奇有限公司 |
用于抑制糖皮质素受体(gcr)基因表达的组合物和方法
|
WO2011054939A2
(en)
|
2009-11-09 |
2011-05-12 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of kif10 genes
|
US20110152349A1
(en)
|
2009-12-18 |
2011-06-23 |
Anke Geick |
Compositions and methods for inhibiting expression of il-18 genes
|
US20110196016A1
(en)
*
|
2010-02-05 |
2011-08-11 |
Anke Geick |
Compositions and Methods for Inhibiting Expression of IKK2 Genes
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
CA2794187C
(en)
|
2010-03-24 |
2020-07-14 |
Rxi Pharmaceuticals Corporation |
Rna interference in ocular indications
|
CN110042099A
(zh)
|
2010-03-24 |
2019-07-23 |
菲奥医药公司 |
皮肤与纤维化症候中的rna干扰
|
EP2630240A1
(de)
|
2010-10-18 |
2013-08-28 |
Arrowhead Research Corporation |
Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
|
PT2726613T
(pt)
|
2011-06-30 |
2018-10-26 |
Arrowhead Pharmaceuticals Inc |
Composições e métodos para inibição da expressão de genes do vírus da hepatite b
|
US10519446B2
(en)
|
2013-10-04 |
2019-12-31 |
Novartis Ag |
Organic compounds to treat hepatitis B virus
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
JP6694811B2
(ja)
|
2013-10-04 |
2020-05-20 |
ノバルティス アーゲー |
RNA干渉に使用するためのRNAi剤用の3’末端キャップ
|
JP6772062B2
(ja)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
癌の免疫療法
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
US10900039B2
(en)
|
2014-09-05 |
2021-01-26 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
|
EP3319614B1
(de)
|
2015-07-06 |
2020-12-23 |
Phio Pharmaceuticals Corp. |
Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
CA2991639A1
(en)
|
2015-08-07 |
2017-02-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai therapy for hepatitis b virus infection
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
US20190247436A1
(en)
|
2016-07-21 |
2019-08-15 |
Maxcyte, Inc. |
Methods and compositions for modifying genomic dna
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
WO2018132432A1
(en)
|
2017-01-10 |
2018-07-19 |
Arrowhead Pharmaceuticals, Inc. |
Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use
|
MX2020011570A
(es)
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Administracion extrahepatica.
|
CN114340664A
(zh)
|
2019-06-18 |
2022-04-12 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
|
AU2020297008A1
(en)
|
2019-06-18 |
2022-02-17 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis B virus (HBV) vaccines and HBV-targeting RNAi
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
WO2024097674A2
(en)
*
|
2022-11-02 |
2024-05-10 |
Aligos Therapeutics, Inc. |
Modified short interfering nucleic acid (sina) molecules and uses thereof
|